01

A commercial business, not a research program.

AlgoraeRx is an operating commercial division backed by executed supply agreements with globally credentialled manufacturers, a non-dilutive financing facility, and a leadership team with more than 60 years’ experience scaling pharmaceutical distribution at an institutional level in Australia. Revenue comes from medicines already manufactured and distributed in highly regulated global markets.

02

Capital-efficient model built for the Australian market.

AlgoraeRx’s Source–Register–Supply model is purpose-built to ensure we are brining critical medications to the markets we serve.

Our financing structure contributes to inventory funding, supporting commercial execution and minimalizing shareholder dilution.

03

Discovery optionality: the upside you get for free.

AlgoraeOS has been developed in partnership with the UNSW AI Institute and CSIRO Data61 and is independently validated at the Peter MacCallum Cancer Centre. The platform IP is 100% owned by Algorae and accelerates the development of our long-term pipeline.

AlgoraeOS runs independently of the AlgoraeRx commercial business. You don’t need to believe in AlgoraeOS to invest in AlgoraeRx – but if the platform generates a licensing deal, that value flows directly to shareholders. That asymmetry is the Algorae investment case.